0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

DIOXYANTHRANOL 1-8 AS A SUBSTITUTE FOR CHRYSAROBIN

HERMAN BEERMAN, M.D.; GEORGE V. KULCHAR, M.D.; DONALD M. PILLSBURY, M.D.; JOHN H. STOKES, M.D.
JAMA. 1935;104(1):26-29. doi:10.1001/jama.1935.02760010028005.
Text Size: A A A
Published online

The chemical compound dioxyanthranol 1-8 differs in its structural formula from chrysarobin by the lack of the methyl group. It is formed by reduction from dioxyanthraquinone 1-8, a substance used in industry. Dioxyanthranol 1-8, under the trade name Cignolin, was introduced into dermatology in 1916 as a substitute for chrysarobin by Galewsky1 and Unna.2 The latter carried through elaborate studies of its action on normal and diseased epidermis and showed that the elimination of the methyl group was responsible for the superior activity of the drug, that the 1-8 position of the hydroxyl groups in both chrysarobin and dioxyanthranol is responsible for the antisporiatic effect, and that the latter is approximately from two to five times as effective as the former on the same patient. Apparently, owing to manufacturing difficulties, it was withdrawn from the market in 1924 over the protest of Grumach3 and Hauck,4 but

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();